Presently, only atropine, pirenzepine, and 7-methylxanthine are shown to reduce myopia progression in human trials.
The researchers concluded that topical low-dose atropine appears to be safe and effective in a cohort of European schoolchildren.
Combined interventions for myopia will potentially influence the standard of care.
Existing evidence has failed to convince doctors to uniformly embrace treatments for myopic progression control.
A summary of the LAMP Study results
When should one start atropine treatment for myopes?
There are a range of interventions that can reduce myopia progression.
No one treatment is 100% effective at slowing the rate of myopia progression.
Implicit in deciding when to initiate myopia management is monitoring pre-myopic patients who are at risk of developing myopia.
Atropine has been the apparent hero of myopia management since the 2006 publication of the ATOM (atropine for the treatment of childhood...
Over 30 percent of the world is currently myopic, and by 2050, almost 50 percent will be myopic… a staggering 5 billion...
For most eyecare professionals (ECPs), progressive myopia, especially among children, is a refractive error that they correct with single vision spectacles or...
Today’s optometrist can finally offer our young myopes an alternative to traditional refractive error correction that can improve their quality of life...
Effective management in children and young adults may require different interventions. Learn which works best for your case.